"Leukemia, B-Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant disease of the B-LYMPHOCYTES in the bone marrow and/or blood.
| Descriptor ID |
D015448
|
| MeSH Number(s) |
C04.557.337.428.080 C15.604.515.560.080 C20.683.515.528.080
|
| Concept/Terms |
Leukemia, B-Cell- Leukemia, B-Cell
- Leukemia, B Cell
- Lymphocytic Leukemia, B-Cell
- B-Cell Lymphocytic Leukemia
- B-Cell Lymphocytic Leukemias
- Leukemia, B-Cell Lymphocytic
- Leukemias, B-Cell Lymphocytic
- Lymphocytic Leukemia, B Cell
- Lymphocytic Leukemias, B-Cell
- Leukemia, Lymphocytic, B Cell
- Leukemia, Lymphocytic, B-Cell
- B-Cell Leukemia
- B Cell Leukemia
- B-Cell Leukemias
- Leukemias, B-Cell
- B-Lymphocytic Leukemia
- B Lymphocytic Leukemia
- B-Lymphocytic Leukemias
- Leukemia, B-Lymphocytic
- Leukemias, B-Lymphocytic
|
Below are MeSH descriptors whose meaning is more general than "Leukemia, B-Cell".
Below are MeSH descriptors whose meaning is more specific than "Leukemia, B-Cell".
This graph shows the total number of publications written about "Leukemia, B-Cell" by people in this website by year, and whether "Leukemia, B-Cell" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1997 | 1 | 1 | 2 |
| 1998 | 0 | 1 | 1 |
| 2000 | 2 | 0 | 2 |
| 2001 | 3 | 0 | 3 |
| 2003 | 1 | 2 | 3 |
| 2005 | 2 | 1 | 3 |
| 2006 | 4 | 0 | 4 |
| 2008 | 1 | 1 | 2 |
| 2010 | 2 | 0 | 2 |
| 2011 | 1 | 0 | 1 |
| 2013 | 3 | 0 | 3 |
| 2014 | 3 | 1 | 4 |
| 2015 | 2 | 1 | 3 |
| 2016 | 3 | 1 | 4 |
| 2017 | 4 | 0 | 4 |
| 2019 | 1 | 1 | 2 |
| 2020 | 2 | 0 | 2 |
| 2021 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Leukemia, B-Cell" by people in Profiles.
-
DYRK1a mediates BAFF-induced noncanonical NF-?B activation to promote autoimmunity and B-cell leukemogenesis. Blood. 2021 12 09; 138(23):2360-2371.
-
Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells. Blood. 2021 10 21; 138(16):1391-1405.
-
Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors. Circ Res. 2021 06 11; 128(12):1973-1987.
-
Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA. 2021 03 02; 325(9):833-842.
-
Selecting the Optimal CAR-T for the Treatment of B-Cell Malignancies. Curr Hematol Malig Rep. 2021 02; 16(1):32-39.
-
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat Med. 2020 10; 26(10):1569-1575.
-
CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression. Leukemia. 2021 01; 35(1):75-89.
-
Bruton Tyrosine Kinase Inhibitors: Present and Future. Cancer J. 2019 Nov/Dec; 25(6):386-393.
-
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019 09 12; 134(11):851-859.
-
Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 11; 15(11):1414-1427.